Evotec and Claris Ventures Partner to Accelerate Biotech Clinical Programs

Evotec SE and Claris Ventures announced a new agreement aimed at streamlining pre-clinical and clinical development processes for Claris's portfolio companies. The partnership highlights the union between Evotec's comprehensive development capabilities and Claris's focused investment in biotech firms approaching clinical trials. This collaboration builds upon a successful interaction with IAMA Therapeutics, marking significant progress in drug development and manufacturing.

Claris's portfolio spans across companies in Italy, Switzerland, and the UK, supporting these entities from pre-clinical stages through to first-in-human trials. The agreement with Evotec encompasses a range of services, aiming to enhance the progression of therapies from discovery to clinical evaluation seamlessly. The ongoing cooperation with IAMA Therapeutics illustrates the effective implementation of this model, as Evotec's services were instrumental in advancing IAMA's lead program, IAMA-6, into clinical trials.

The strategic partnership will provide Claris's portfolio companies with easier access to Evotec's services, supporting them through a governance model designed for success in integrated program advancements. Officials from both Evotec and Claris Ventures expressed enthusiasm for the collaboration's capacity to expedite the development of innovative treatments and address unmet medical needs more efficiently.